Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive trial of artemisinin-based therapies for malaria in African children
PACTR202509766285920Phase 3Not yet recruiting
- Sponsor
- Medical University of Vienna
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of artemether + lumefantrine, artesunate + amodiaquine, dihydroartemisinin + piperaquine, artesunate + mefloquine and artesunate + pyronaridine in Malaria (5 arms), sponsored by Medical University of Vienna. Primary endpoint: Day 42 PCR-corrected adequate clinical and parasitological response. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
artemether + lumefantrineartesunate + amodiaquinedihydroartemisinin + piperaquineartesunate + mefloquineartesunate + pyronaridine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202509766285920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509766285920.